There were 29 press releases posted in the last 24 hours and 154,929 in the last 365 days.

ImmusanT to Present New Findings on Celiac Disease and Lead Therapeutic Candidate During the Digestive Disease Week Annual Conference 2019

/EIN News/ -- CAMBRIDGE, Mass., May 16, 2019 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based immunomodulatory vaccine therapies to patients with autoimmune diseases, announced today the company will be presenting two abstracts supporting its lead therapeutic candidate, Nexvax2®, during the upcoming Digestive Disease Week Annual Conference 2019, being held in San Diego on May 18-21, 2019.

Presentation Details:

Presentation Title:   A Randomized, Placebo-Controlled Evaluation of the Clinical Tolerability, Pharmacodynamic (PD) & Pharmacokinetic (PK) Profiles of Subcutaneous (SC) Versus Intradermal (ID) Dosing of Nexvax2, a Peptide Treatment for Celiac Disease (CED)
Presentation Date:   Tuesday, May 21, 2019
Presentation Time:   8:24 a.m. – 8:36 a.m. PDT
Location:   Room 20A, San Diego Convention Center
Presentation Title:   Acute Gluten-Induced Symptoms in Celiac Disease (CED) are Quantitatively Correlated with Serum Cytokine Response
Presentation Date:   Tuesday, May 21, 2019
Presentation Time:   9:00 a.m. – 9:12 a.m. PDT
Location:   Room 20A, San Diego Convention Center

About ImmusanT, Inc.

At ImmusanT, we are developing a new class of therapeutic vaccines to change the lives of people living with autoimmune diseases. Our Epitope-Specific Immuno-Therapy™ (ESIT™) platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes. Our lead program, Nexvax2®, is in clinical development with the goal of protecting celiac disease patients against the debilitating effects of gluten.

Media Contact:

Andrew Mielach
Associate Director
LifeSci Public Relations
(646) 876-5868


Distribution channels: Conferences & Trade Fairs

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.